Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
Background Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and $ CD8^{+} $ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. Materials and methods We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. Results We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. Conclusions Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
---|---|
Enthalten in: |
Cancer immunology immunotherapy - 70(2021), 11 vom: 10. Apr., Seite 3277-3289 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Arranz-Nicolás, Javier [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Combination |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
---|
doi: |
10.1007/s00262-021-02924-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2077149981 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2077149981 | ||
003 | DE-627 | ||
005 | 20230516050045.0 | ||
007 | tu | ||
008 | 221220s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00262-021-02924-5 |2 doi | |
035 | |a (DE-627)OLC2077149981 | ||
035 | |a (DE-He213)s00262-021-02924-5-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Arranz-Nicolás, Javier |e verfasserin |0 (orcid)0000-0003-4678-9222 |4 aut | |
245 | 1 | 0 | |a Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
520 | |a Background Antibody-based therapies blocking the programmed cell death-1/ligand-1 (PD-1/PD-L1) axis have provided unprecedent clinical success in cancer treatment. Acquired resistance, however, frequently occurs, commonly associated with the upregulation of additional inhibitory molecules. Diacylglycerol kinase (DGK) α limits the extent of Ras activation in response to antigen recognition, and its upregulation facilitates hypofunctional, exhausted T cell states. Pharmacological DGKα targeting restores cytotoxic function of chimeric antigen receptor and $ CD8^{+} $ T cells isolated from solid tumors, suggesting a mechanism to reverse T cell exhausted phenotypes. Nevertheless, the contribution of DGKα downstream of the PD-1/PD-L1 inhibitory axis in human T cells and the consequences of combining DGKα and anti-PD-1/PD-L1 inhibitors are still unresolved relevant issues. Materials and methods We used a human triple parameter reporter cell line to investigate DGKα contribution to the PD-1/PD-L1 inhibitory pathway. We also addressed the impact of deleting DGKα expression in the growth dynamics and systemic tumor-derived effects of a PD-1-related tumor model, the MC38 colon adenocarcinoma. Results We identify DGKα as a contributor to the PD-1/PD-L1 axis that strongly limits the Ras/ERK/AP-1 pathway. DGKα function reinforces exhausted T cell phenotypes ultimately promoting tumor growth and generalized immunosuppression. Pharmacological DGKα inhibition selectively enhances AP-1 transcription and, importantly, cooperates with antibodies blocking the PD-1/PD-L1 interrelation. Conclusions Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer. | ||
650 | 4 | |a T Lymphocytes | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a Drug Therapy | |
650 | 4 | |a Combination | |
650 | 4 | |a Programmed Cell Death-1 | |
650 | 4 | |a Diacylglycerol Kinase | |
700 | 1 | |a Martin-Salgado, Miguel |4 aut | |
700 | 1 | |a Adán-Barrientos, Irene |4 aut | |
700 | 1 | |a Liébana, Rosa |4 aut | |
700 | 1 | |a del Carmen Moreno-Ortíz, María |4 aut | |
700 | 1 | |a Leitner, Judith |4 aut | |
700 | 1 | |a Steinberger, Peter |4 aut | |
700 | 1 | |a Ávila-Flores, Antonia |0 (orcid)0000-0001-6278-2472 |4 aut | |
700 | 1 | |a Merida, Isabel |0 (orcid)0000-0003-2762-6241 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Springer Berlin Heidelberg, 1976 |g 70(2021), 11 vom: 10. Apr., Seite 3277-3289 |w (DE-627)129442712 |w (DE-600)195342-4 |w (DE-576)014812193 |x 0340-7004 |7 nnns |
773 | 1 | 8 | |g volume:70 |g year:2021 |g number:11 |g day:10 |g month:04 |g pages:3277-3289 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00262-021-02924-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_4277 | ||
936 | b | k | |a 44.00 |q VZ |
951 | |a AR | ||
952 | |d 70 |j 2021 |e 11 |b 10 |c 04 |h 3277-3289 |